Myasthenia Gravis Treatment Market By Drug class (Monoclonal antibodies, Intravenous immunoglobulin, Others), By Age group (Below 55 years, Above 55 years), By Distribution channel (Hospital pharmacies, Drug store and retail pharmacies, Online providers): Global Opportunity Analysis and Industry Forecast, 2023-2032

Myasthenia Gravis Treatment Market

Myasthenia gravis is a chronic autoimmune neuromuscular disorder that leads to muscle weakness and fatigue, especially in the muscles responsible for eye movements, facial expressions, swallowing, and breathing. It occurs due to an abnormal immune response that attacks the acetylcholine receptors (AChR) or other proteins at the neuromuscular junction, resulting in a decrease in the number of functional acetylcholine receptors (AChR) and impaired nerve-muscle communication. 

Key factors driving the growth of the myasthenia gravis treatment market are increasing prevalence of autoimmune disorders, wide availability of therapeutics for myasthenia gravis and increasing awareness about the early diagnosis and treatment. For instance, according to the Myasthenia Gravis Foundation of America, there are currently over 100,000 people in the U.S. with myasthenia gravis, and the number is increasing every year. As the prevalence of the disease grows, there is a corresponding increase in demand for effective treatments. In addition, rise in awareness and understanding of myasthenia gravis, more patients are being diagnosed and seeking treatment. The increasing awareness of the disease is driving the demand for effective therapies that can help manage symptoms and improve quality of life.

Further, development of new diagnostic tools and therapies is driving the growth of the myasthenia gravis treatment market. For instance, recent advances in immunotherapy have led to the development of new drugs that can suppress the immune system and reduce the production of harmful antibodies. Moreover, pharmaceutical companies are investing heavily in research and development to identify new treatments and therapies for myasthenia gravis. This investment is driving the development of new drugs and therapies that can effectively manage the symptoms of the disease.

In addition, rise in adoption of novel therapeutics for managing the symptoms of myasthenia gravis is expected to fuel the growth of market. For instance, article published by Neuromuscular Disorders in 2022, stated that, 40% of the myasthenia gravis patients used corticosteroids and 30% immunosuppressants, thus rise in adoption of such drugs for myasthenia gravis drives the growth of market. Furthermore, rise in regulatory approval and rise in adoption of monoclonal antibody for myasthenia gravis is anticipated to fuel the growth of market. For instance, in August 2022, Japanese Ministry of Health, Labour and Welfare (MHLW) approved Ultomiris (ravulizumab) for the treatment of adult patients with generalized myasthenia gravis in Japan, thus propelling the growth of market.

Further, advancements in research and development of novel drugs are key driver of the myasthenia gravis treatment market. Researchers are continually exploring new treatment options, including immunomodulatory drugs, targeted therapies, biologics, and monoclonal antibody. These drugs are designed to selectively target the underlying causes of the disease and provide more effective and targeted treatment options. For instance, U.S. National Library of Medicine in 2022, stated that inebilizumab (anti-CD19 cytolytic monoclonal antibody) is in phase 3 clinical studies for the treatment of myasthenia gravis. These drug works by targeting specific immune cells that are responsible for attacking the neuromuscular junction, leading to improved symptom control and disease management.

The market also offers growth opportunities to the key players in the market.  Many developing regions such India and Brazil offer lucrative opportunities to key players of myasthenia gravis treatment market owing to high population base, increase in demand of novel therapeutics owing to increase in autoimmune disorders and rise healthcare spending. In addition, rise in disposable income and medical tourism fuels the growth of myasthenia gravis treatment market. 

The myasthenia gravis treatment market is segmented into drug class, age group, distribution channel, and region. On the basis of drug class, the market is categorized into monoclonal antibodies, intravenous immunoglobulin and others. On the basis of age group, the market is bifurcated into below 55 years and above 55 years. On the basis of distribution channel, the market is segregated into hospital pharmacies, drug stores & retail pharmacies, and online providers. Region wise, the market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (Japan, China, India and rest of Asia-Pacific), and LAMEA (Latin America and Middle East & Africa).

The key players profiled in the study include F. Hoffmann-La Roche Ltd., AstraZeneca, Novartis AG, Zydus Lifesciences Limited, Bausch Health Companies, Inc., CSL Limited, Grifols, S.A., Octapharma AG, Astellas Pharma Inc., and Kedrion, SpA.

Key Market Insights (Updated)

•    On the basis of drug class, the others segment dominated the market in terms of revenue in 2022. 

•    On the basis of age group, below 55 years segment dominated the market in terms of revenue in 2022. 

•    On the basis of distribution channel, the drug stores and retail pharmacies segment dominated the market in terms of revenue in 2022. 

•    Region wise, North America generated the largest revenue in 2022. However, Asia-Pacific is anticipated to grow at the highest CAGR during the forecast period.

 

Overview

The global myasthenia gravis treatment market was valued at $1.7 billion in 2022, and is projected to reach $3.1 billion by 2032, growing at a CAGR of 6.5% from 2023 to 2032.

Myasthenia gravis (MG) is an autoimmune disease caused by antibodies that attack and damage the receptors at the neuromuscular junction, leading to muscle weakness and fatigue. In addition, the antibodies target the acetylcholine receptor (AChR), which is a protein located on the postsynaptic membrane of the neuromuscular junction. Moreover, in some cases, the antibodies may target other proteins related to the acetylcholine receptor (AChR), such as muscle-specific kinase (MuSK). This leads to impaired communication between the nerve and muscle, which results in muscle weakness and fatigue.  

The most common symptoms of myasthenia gravis include muscle weakness, particularly in the eyes, face, throat & limbs, difficulty speaking, swallowing, or breathing, drooping eyelids, double vision, and fatigue that worsens with activity. Currently, there are several drugs available for the treatment of myasthenia gravis, such as acetylcholinesterase inhibitors, corticosteroids, immunosuppressants, intravenous immunoglobulin (IVIg), and monoclonal antibodies. 

The major factor driving the growth of myasthenia gravis treatment market are increase in number of patients suffering from myasthenia gravis, advancements in diagnosis of autoimmune disorders, and rise in availability of treatment options for myasthenia gravis. The rise in prevalence of myasthenia gravis worldwide is one of the primary drivers for the growth of the myasthenia gravis treatment market. For instance, according to the Myasthenia Gravis Foundation of America, approximately 14 to 20 out of 100,000 people in the U.S. are affected by myasthenia gravis, and the disease is more common in women than men. Moreover, the incidence of myasthenia gravis has increased globally, which is expected to drive the demand for effective treatments for the disease. 

Furthermore, increase in the diagnosis of myasthenia gravis is expected to fuel the market growth. Myasthenia gravis is a rare and often misdiagnosed autoimmune disorder that affects the neuromuscular junction, leading to muscle weakness and fatigue. The disease can be challenging to diagnose, as symptoms may be subtle or vary greatly from person to person. However, advancements in diagnostic techniques have led to more accurate and timely diagnosis of myasthenia gravis, which drives the market growth. The surge in the diagnosis of myasthenia gravis has increased the demand for effective treatments and fosters market growth. As more cases of myasthenia gravis are identified and diagnosed earlier, there is a greater need for effective treatments to manage the disease and prevent complications. This has led to increased investment in R&D  of new and more effective treatments for myasthenia gravis.  

Furthermore, the increase in diagnosis has led to greater awareness of the disease among patients and healthcare professionals. In addition, increase in number of drugs in clinical stages of development, focused on treatment of myasthenia gravis is anticipated to boost the growth of market. As the number of people affected by myasthenia gravis continues to increase, the demand for effective treatments rises, resulting in need for innovative therapies. This demand drives the pharmaceutical companies and research institutions to invest in the development of new treatments for the disease, with clinical trials serving as a critical tool for testing their safety and efficacy. Thus, upsurge in number of clinical trials focused on myasthenia gravis is expected to drive the growth of the myasthenia gravis treatment market by providing new and improved treatments for patients suffering from myasthenia gravis disease. 

The myasthenia gravis treatment market is segmented into drug class, age group, distribution channel, and region. On the basis of drug class, the market is categorized into cholinesterase inhibitors, immunosuppressants, monoclonal antibodies, intravenous immunoglobulin (IVIg), and others. On the basis of age group, the market is bifurcated into below 50 years and above 50 years. On the basis of distribution channel, the market is segregated into hospital pharmacies, drug stores & retail pharmacies, and online providers. Region wise, the market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (Japan, China, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA). 

Major key players that operate in the global myasthenia gravis treatment market are F. Hoffmann-La Roche Ltd., AstraZeneca, Novartis AG, Zydus Lifesciences Limited, Bausch Health Companies, Inc., CSL Limited, Grifols, S.A., Octapharma AG, Astellas Pharma Inc., and Kedrion, SpA. The key players have adopted strategies such as acquisition, agreement, strategic alliance, product approval, and expansion to expand their product portfolio. 

Key Benefits For Stakeholders

●This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the myasthenia gravis treatment market analysis from 2022 to 2032 to identify the prevailing myasthenia gravis treatment market opportunities.

●The market research is offered along with information related to key drivers, restraints, and opportunities.

●Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.

●In-depth analysis of the myasthenia gravis treatment market segmentation assists to determine the prevailing market opportunities.

●Major countries in each region are mapped according to their revenue contribution to the global market.

●Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.

●The report includes the analysis of the regional as well as global myasthenia gravis treatment market trends, key players, market segments, application areas, and market growth strategies.

Key Market Segments

○ Zydus Lifesciences Limite

Scope of Myasthenia Gravis Treatment Market Report

1.1. Report description

1.2. Key market segments

1.3. Key benefits to the stakeholders

1.4. Research Methodology

1.4.1. Primary research

1.4.2. Secondary research

1.4.3. Analyst tools and models

2.1. CXO Perspective

3.1. Market definition and scope

3.2. Key findings

3.2.1. Top impacting factors

3.2.2. Top investment pockets

3.3. Porter’s five forces analysis

3.3.1. Bargaining power of suppliers

3.3.2. Bargaining power of buyers

3.3.3. Threat of substitutes

3.3.4. Threat of new entrants

3.3.5. Intensity of rivalry

3.4. Market dynamics

3.4.1. Drivers

3.4.1.1. Rise in demand of effective treatments for myasthenia gravis

3.4.1.2. Surge in prevalence of myasthenia gravis

3.4.1.3. Advancements in R&D of novel drugs

3.4.2. Restraints

3.4.2.1. Side effects and high cost associated with treatments for myasthenia gravis

3.4.3. Opportunities

3.4.3.1. Growth opportunities in emerging markets

3.5. COVID-19 Impact Analysis on the market

4.1. Overview

4.1.1. Market size and forecast

4.2. Monoclonal antibodies

4.2.1. Key market trends, growth factors and opportunities

4.2.2. Market size and forecast, by region

4.2.3. Market share analysis by country

4.3. Intravenous immunoglobulin

4.3.1. Key market trends, growth factors and opportunities

4.3.2. Market size and forecast, by region

4.3.3. Market share analysis by country

4.4. Others

4.4.1. Key market trends, growth factors and opportunities

4.4.2. Market size and forecast, by region

4.4.3. Market share analysis by country

5.1. Overview

5.1.1. Market size and forecast

5.2. Below 55 years

5.2.1. Key market trends, growth factors and opportunities

5.2.2. Market size and forecast, by region

5.2.3. Market share analysis by country

5.3. Above 55 years

5.3.1. Key market trends, growth factors and opportunities

5.3.2. Market size and forecast, by region

5.3.3. Market share analysis by country

6.1. Overview

6.1.1. Market size and forecast

6.2. Hospital pharmacies

6.2.1. Key market trends, growth factors and opportunities

6.2.2. Market size and forecast, by region

6.2.3. Market share analysis by country

6.3. Drug store and retail pharmacies

6.3.1. Key market trends, growth factors and opportunities

6.3.2. Market size and forecast, by region

6.3.3. Market share analysis by country

6.4. Online providers

6.4.1. Key market trends, growth factors and opportunities

6.4.2. Market size and forecast, by region

6.4.3. Market share analysis by country

7.1. Overview

7.1.1. Market size and forecast By Region

7.2. North America

7.2.1. Key trends and opportunities

7.2.2. Market size and forecast, by Drug class

7.2.3. Market size and forecast, by Age group

7.2.4. Market size and forecast, by Distribution channel

7.2.5. Market size and forecast, by country

7.2.5.1. U.S.

7.2.5.1.1. Key market trends, growth factors and opportunities

7.2.5.1.2. Market size and forecast, by Drug class

7.2.5.1.3. Market size and forecast, by Age group

7.2.5.1.4. Market size and forecast, by Distribution channel

7.2.5.2. Canada

7.2.5.2.1. Key market trends, growth factors and opportunities

7.2.5.2.2. Market size and forecast, by Drug class

7.2.5.2.3. Market size and forecast, by Age group

7.2.5.2.4. Market size and forecast, by Distribution channel

7.2.5.3. Mexico

7.2.5.3.1. Key market trends, growth factors and opportunities

7.2.5.3.2. Market size and forecast, by Drug class

7.2.5.3.3. Market size and forecast, by Age group

7.2.5.3.4. Market size and forecast, by Distribution channel

7.3. Europe

7.3.1. Key trends and opportunities

7.3.2. Market size and forecast, by Drug class

7.3.3. Market size and forecast, by Age group

7.3.4. Market size and forecast, by Distribution channel

7.3.5. Market size and forecast, by country

7.3.5.1. Germany

7.3.5.1.1. Key market trends, growth factors and opportunities

7.3.5.1.2. Market size and forecast, by Drug class

7.3.5.1.3. Market size and forecast, by Age group

7.3.5.1.4. Market size and forecast, by Distribution channel

7.3.5.2. France

7.3.5.2.1. Key market trends, growth factors and opportunities

7.3.5.2.2. Market size and forecast, by Drug class

7.3.5.2.3. Market size and forecast, by Age group

7.3.5.2.4. Market size and forecast, by Distribution channel

7.3.5.3. UK

7.3.5.3.1. Key market trends, growth factors and opportunities

7.3.5.3.2. Market size and forecast, by Drug class

7.3.5.3.3. Market size and forecast, by Age group

7.3.5.3.4. Market size and forecast, by Distribution channel

7.3.5.4. Italy

7.3.5.4.1. Key market trends, growth factors and opportunities

7.3.5.4.2. Market size and forecast, by Drug class

7.3.5.4.3. Market size and forecast, by Age group

7.3.5.4.4. Market size and forecast, by Distribution channel

7.3.5.5. Spain

7.3.5.5.1. Key market trends, growth factors and opportunities

7.3.5.5.2. Market size and forecast, by Drug class

7.3.5.5.3. Market size and forecast, by Age group

7.3.5.5.4. Market size and forecast, by Distribution channel

7.3.5.6. Rest of Europe

7.3.5.6.1. Key market trends, growth factors and opportunities

7.3.5.6.2. Market size and forecast, by Drug class

7.3.5.6.3. Market size and forecast, by Age group

7.3.5.6.4. Market size and forecast, by Distribution channel

7.4. Asia-Pacific

7.4.1. Key trends and opportunities

7.4.2. Market size and forecast, by Drug class

7.4.3. Market size and forecast, by Age group

7.4.4. Market size and forecast, by Distribution channel

7.4.5. Market size and forecast, by country

7.4.5.1. Japan

7.4.5.1.1. Key market trends, growth factors and opportunities

7.4.5.1.2. Market size and forecast, by Drug class

7.4.5.1.3. Market size and forecast, by Age group

7.4.5.1.4. Market size and forecast, by Distribution channel

7.4.5.2. China

7.4.5.2.1. Key market trends, growth factors and opportunities

7.4.5.2.2. Market size and forecast, by Drug class

7.4.5.2.3. Market size and forecast, by Age group

7.4.5.2.4. Market size and forecast, by Distribution channel

7.4.5.3. India

7.4.5.3.1. Key market trends, growth factors and opportunities

7.4.5.3.2. Market size and forecast, by Drug class

7.4.5.3.3. Market size and forecast, by Age group

7.4.5.3.4. Market size and forecast, by Distribution channel

7.4.5.4. Rest of Asia-Pacific

7.4.5.4.1. Key market trends, growth factors and opportunities

7.4.5.4.2. Market size and forecast, by Drug class

7.4.5.4.3. Market size and forecast, by Age group

7.4.5.4.4. Market size and forecast, by Distribution channel

7.5. LAMEA

7.5.1. Key trends and opportunities

7.5.2. Market size and forecast, by Drug class

7.5.3. Market size and forecast, by Age group

7.5.4. Market size and forecast, by Distribution channel

7.5.5. Market size and forecast, by country

7.5.5.1. Latin America

7.5.5.1.1. Key market trends, growth factors and opportunities

7.5.5.1.2. Market size and forecast, by Drug class

7.5.5.1.3. Market size and forecast, by Age group

7.5.5.1.4. Market size and forecast, by Distribution channel

7.5.5.2. Middle East And Africa

7.5.5.2.1. Key market trends, growth factors and opportunities

7.5.5.2.2. Market size and forecast, by Drug class

7.5.5.2.3. Market size and forecast, by Age group

7.5.5.2.4. Market size and forecast, by Distribution channel

8.1. Introduction

8.2. Top winning strategies

8.3. Product Mapping of Top 10 Player

8.4. Competitive Dashboard

8.5. Competitive Heatmap

8.6. Top player positioning, 2022

9.1. Zydus Lifesciences Limited

9.1.1. Company overview

9.1.2. Key Executives

9.1.3. Company snapshot

9.1.4. Operating business segments

9.1.5. Product portfolio

9.1.6. Business performance

9.2. Novartis AG

9.2.1. Company overview

9.2.2. Key Executives

9.2.3. Company snapshot

9.2.4. Operating business segments

9.2.5. Product portfolio

9.2.6. Business performance

9.3. AstraZeneca

9.3.1. Company overview

9.3.2. Key Executives

9.3.3. Company snapshot

9.3.4. Operating business segments

9.3.5. Product portfolio

9.3.6. Business performance

9.3.7. Key strategic moves and developments

9.4. Bausch Health Companies, Inc.

9.4.1. Company overview

9.4.2. Key Executives

9.4.3. Company snapshot

9.4.4. Operating business segments

9.4.5. Product portfolio

9.4.6. Business performance

9.5. CSL Limited

9.5.1. Company overview

9.5.2. Key Executives

9.5.3. Company snapshot

9.5.4. Operating business segments

9.5.5. Product portfolio

9.5.6. Business performance

9.5.7. Key strategic moves and developments

9.6. Grifols, S.A.

9.6.1. Company overview

9.6.2. Key Executives

9.6.3. Company snapshot

9.6.4. Operating business segments

9.6.5. Product portfolio

9.6.6. Business performance

9.6.7. Key strategic moves and developments

9.7. Octapharma AG

9.7.1. Company overview

9.7.2. Key Executives

9.7.3. Company snapshot

9.7.4. Operating business segments

9.7.5. Product portfolio

9.7.6. Business performance

9.8. Astellas Pharma Inc.

9.8.1. Company overview

9.8.2. Key Executives

9.8.3. Company snapshot

9.8.4. Operating business segments

9.8.5. Product portfolio

9.8.6. Business performance

9.9. Kedrion, SpA

9.9.1. Company overview

9.9.2. Key Executives

9.9.3. Company snapshot

9.9.4. Operating business segments

9.9.5. Product portfolio

9.9.6. Business performance

9.9.7. Key strategic moves and developments

9.10. F. Hoffmann-La Roche Ltd.

9.10.1. Company overview

9.10.2. Key Executives

9.10.3. Company snapshot

9.10.4. Operating business segments

9.10.5. Product portfolio

9.10.6. Business performanc

LIST OF TABLES

TABLE 01. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)

TABLE 02. MYASTHENIA GRAVIS TREATMENT MARKET FOR MONOCLONAL ANTIBODIES, BY REGION, 2022-2032 ($MILLION)

TABLE 03. MYASTHENIA GRAVIS TREATMENT MARKET FOR INTRAVENOUS IMMUNOGLOBULIN, BY REGION, 2022-2032 ($MILLION)

TABLE 04. MYASTHENIA GRAVIS TREATMENT MARKET FOR OTHERS, BY REGION, 2022-2032 ($MILLION)

TABLE 05. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET, BY AGE GROUP, 2022-2032 ($MILLION)

TABLE 06. MYASTHENIA GRAVIS TREATMENT MARKET FOR BELOW 55 YEARS, BY REGION, 2022-2032 ($MILLION)

TABLE 07. MYASTHENIA GRAVIS TREATMENT MARKET FOR ABOVE 55 YEARS, BY REGION, 2022-2032 ($MILLION)

TABLE 08. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)

TABLE 09. MYASTHENIA GRAVIS TREATMENT MARKET FOR HOSPITAL PHARMACIES, BY REGION, 2022-2032 ($MILLION)

TABLE 10. MYASTHENIA GRAVIS TREATMENT MARKET FOR DRUG STORE AND RETAIL PHARMACIES, BY REGION, 2022-2032 ($MILLION)

TABLE 11. MYASTHENIA GRAVIS TREATMENT MARKET FOR ONLINE PROVIDERS, BY REGION, 2022-2032 ($MILLION)

TABLE 12. MYASTHENIA GRAVIS TREATMENT MARKET, BY REGION, 2022-2032 ($MILLION)

TABLE 13. NORTH AMERICA MYASTHENIA GRAVIS TREATMENT MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)

TABLE 14. NORTH AMERICA MYASTHENIA GRAVIS TREATMENT MARKET, BY AGE GROUP, 2022-2032 ($MILLION)

TABLE 15. NORTH AMERICA MYASTHENIA GRAVIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)

TABLE 16. NORTH AMERICA MYASTHENIA GRAVIS TREATMENT MARKET, BY COUNTRY, 2022-2032 ($MILLION)

TABLE 17. U.S. MYASTHENIA GRAVIS TREATMENT MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)

TABLE 18. U.S. MYASTHENIA GRAVIS TREATMENT MARKET, BY AGE GROUP, 2022-2032 ($MILLION)

TABLE 19. U.S. MYASTHENIA GRAVIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)

TABLE 20. CANADA MYASTHENIA GRAVIS TREATMENT MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)

TABLE 21. CANADA MYASTHENIA GRAVIS TREATMENT MARKET, BY AGE GROUP, 2022-2032 ($MILLION)

TABLE 22. CANADA MYASTHENIA GRAVIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)

TABLE 23. MEXICO MYASTHENIA GRAVIS TREATMENT MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)

TABLE 24. MEXICO MYASTHENIA GRAVIS TREATMENT MARKET, BY AGE GROUP, 2022-2032 ($MILLION)

TABLE 25. MEXICO MYASTHENIA GRAVIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)

TABLE 26. EUROPE MYASTHENIA GRAVIS TREATMENT MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)

TABLE 27. EUROPE MYASTHENIA GRAVIS TREATMENT MARKET, BY AGE GROUP, 2022-2032 ($MILLION)

TABLE 28. EUROPE MYASTHENIA GRAVIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)

TABLE 29. EUROPE MYASTHENIA GRAVIS TREATMENT MARKET, BY COUNTRY, 2022-2032 ($MILLION)

TABLE 30. GERMANY MYASTHENIA GRAVIS TREATMENT MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)

TABLE 31. GERMANY MYASTHENIA GRAVIS TREATMENT MARKET, BY AGE GROUP, 2022-2032 ($MILLION)

TABLE 32. GERMANY MYASTHENIA GRAVIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)

TABLE 33. FRANCE MYASTHENIA GRAVIS TREATMENT MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)

TABLE 34. FRANCE MYASTHENIA GRAVIS TREATMENT MARKET, BY AGE GROUP, 2022-2032 ($MILLION)

TABLE 35. FRANCE MYASTHENIA GRAVIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)

TABLE 36. UK MYASTHENIA GRAVIS TREATMENT MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)

TABLE 37. UK MYASTHENIA GRAVIS TREATMENT MARKET, BY AGE GROUP, 2022-2032 ($MILLION)

TABLE 38. UK MYASTHENIA GRAVIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)

TABLE 39. ITALY MYASTHENIA GRAVIS TREATMENT MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)

TABLE 40. ITALY MYASTHENIA GRAVIS TREATMENT MARKET, BY AGE GROUP, 2022-2032 ($MILLION)

TABLE 41. ITALY MYASTHENIA GRAVIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)

TABLE 42. SPAIN MYASTHENIA GRAVIS TREATMENT MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)

TABLE 43. SPAIN MYASTHENIA GRAVIS TREATMENT MARKET, BY AGE GROUP, 2022-2032 ($MILLION)

TABLE 44. SPAIN MYASTHENIA GRAVIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)

TABLE 45. REST OF EUROPE MYASTHENIA GRAVIS TREATMENT MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)

TABLE 46. REST OF EUROPE MYASTHENIA GRAVIS TREATMENT MARKET, BY AGE GROUP, 2022-2032 ($MILLION)

TABLE 47. REST OF EUROPE MYASTHENIA GRAVIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)

TABLE 48. ASIA-PACIFIC MYASTHENIA GRAVIS TREATMENT MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)

TABLE 49. ASIA-PACIFIC MYASTHENIA GRAVIS TREATMENT MARKET, BY AGE GROUP, 2022-2032 ($MILLION)

TABLE 50. ASIA-PACIFIC MYASTHENIA GRAVIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)

TABLE 51. ASIA-PACIFIC MYASTHENIA GRAVIS TREATMENT MARKET, BY COUNTRY, 2022-2032 ($MILLION)

TABLE 52. JAPAN MYASTHENIA GRAVIS TREATMENT MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)

TABLE 53. JAPAN MYASTHENIA GRAVIS TREATMENT MARKET, BY AGE GROUP, 2022-2032 ($MILLION)

TABLE 54. JAPAN MYASTHENIA GRAVIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)

TABLE 55. CHINA MYASTHENIA GRAVIS TREATMENT MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)

TABLE 56. CHINA MYASTHENIA GRAVIS TREATMENT MARKET, BY AGE GROUP, 2022-2032 ($MILLION)

TABLE 57. CHINA MYASTHENIA GRAVIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)

TABLE 58. INDIA MYASTHENIA GRAVIS TREATMENT MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)

TABLE 59. INDIA MYASTHENIA GRAVIS TREATMENT MARKET, BY AGE GROUP, 2022-2032 ($MILLION)

TABLE 60. INDIA MYASTHENIA GRAVIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)

TABLE 61. REST OF ASIA-PACIFIC MYASTHENIA GRAVIS TREATMENT MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)

TABLE 62. REST OF ASIA-PACIFIC MYASTHENIA GRAVIS TREATMENT MARKET, BY AGE GROUP, 2022-2032 ($MILLION)

TABLE 63. REST OF ASIA-PACIFIC MYASTHENIA GRAVIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)

TABLE 64. LAMEA MYASTHENIA GRAVIS TREATMENT MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)

TABLE 65. LAMEA MYASTHENIA GRAVIS TREATMENT MARKET, BY AGE GROUP, 2022-2032 ($MILLION)

TABLE 66. LAMEA MYASTHENIA GRAVIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)

TABLE 67. LAMEA MYASTHENIA GRAVIS TREATMENT MARKET, BY COUNTRY, 2022-2032 ($MILLION)

TABLE 68. LATIN AMERICA MYASTHENIA GRAVIS TREATMENT MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)

TABLE 69. LATIN AMERICA MYASTHENIA GRAVIS TREATMENT MARKET, BY AGE GROUP, 2022-2032 ($MILLION)

TABLE 70. LATIN AMERICA MYASTHENIA GRAVIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)

TABLE 71. MIDDLE EAST AND AFRICA MYASTHENIA GRAVIS TREATMENT MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)

TABLE 72. MIDDLE EAST AND AFRICA MYASTHENIA GRAVIS TREATMENT MARKET, BY AGE GROUP, 2022-2032 ($MILLION)

TABLE 73. MIDDLE EAST AND AFRICA MYASTHENIA GRAVIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)

TABLE 74. ZYDUS LIFESCIENCES LIMITED: KEY EXECUTIVES

TABLE 75. ZYDUS LIFESCIENCES LIMITED: COMPANY SNAPSHOT

TABLE 76. ZYDUS LIFESCIENCES LIMITED: PRODUCT SEGMENTS

TABLE 77. ZYDUS LIFESCIENCES LIMITED: PRODUCT PORTFOLIO

TABLE 78. NOVARTIS AG: KEY EXECUTIVES

TABLE 79. NOVARTIS AG: COMPANY SNAPSHOT

TABLE 80. NOVARTIS AG: PRODUCT SEGMENTS

TABLE 81. NOVARTIS AG: PRODUCT PORTFOLIO

TABLE 82. ASTRAZENECA: KEY EXECUTIVES

TABLE 83. ASTRAZENECA: COMPANY SNAPSHOT

TABLE 84. ASTRAZENECA: PRODUCT SEGMENTS

TABLE 85. ASTRAZENECA: PRODUCT PORTFOLIO

TABLE 86. ASTRAZENECA: KEY STRATERGIES

TABLE 87. BAUSCH HEALTH COMPANIES, INC.: KEY EXECUTIVES

TABLE 88. BAUSCH HEALTH COMPANIES, INC.: COMPANY SNAPSHOT

TABLE 89. BAUSCH HEALTH COMPANIES, INC.: PRODUCT SEGMENTS

TABLE 90. BAUSCH HEALTH COMPANIES, INC.: PRODUCT PORTFOLIO

TABLE 91. CSL LIMITED: KEY EXECUTIVES

TABLE 92. CSL LIMITED: COMPANY SNAPSHOT

TABLE 93. CSL LIMITED: PRODUCT SEGMENTS

TABLE 94. CSL LIMITED: PRODUCT PORTFOLIO

TABLE 95. CSL LIMITED: KEY STRATERGIES

TABLE 96. GRIFOLS, S.A.: KEY EXECUTIVES

TABLE 97. GRIFOLS, S.A.: COMPANY SNAPSHOT

TABLE 98. GRIFOLS, S.A.: PRODUCT SEGMENTS

TABLE 99. GRIFOLS, S.A.: PRODUCT PORTFOLIO

TABLE 100. GRIFOLS, S.A.: KEY STRATERGIES

TABLE 101. OCTAPHARMA AG: KEY EXECUTIVES

TABLE 102. OCTAPHARMA AG: COMPANY SNAPSHOT

TABLE 103. OCTAPHARMA AG: PRODUCT SEGMENTS

TABLE 104. OCTAPHARMA AG: PRODUCT PORTFOLIO

TABLE 105. ASTELLAS PHARMA INC.: KEY EXECUTIVES

TABLE 106. ASTELLAS PHARMA INC.: COMPANY SNAPSHOT

TABLE 107. ASTELLAS PHARMA INC.: PRODUCT SEGMENTS

TABLE 108. ASTELLAS PHARMA INC.: PRODUCT PORTFOLIO

TABLE 109. KEDRION, SPA: KEY EXECUTIVES

TABLE 110. KEDRION, SPA: COMPANY SNAPSHOT

TABLE 111. KEDRION, SPA: PRODUCT SEGMENTS

TABLE 112. KEDRION, SPA: PRODUCT PORTFOLIO

TABLE 113. KEDRION, SPA: KEY STRATERGIES

TABLE 114. F. HOFFMANN-LA ROCHE LTD.: KEY EXECUTIVES

TABLE 115. F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT

TABLE 116. F. HOFFMANN-LA ROCHE LTD.: PRODUCT SEGMENTS

TABLE 117. F. HOFFMANN-LA ROCHE LTD.: PRODUCT PORTFOLIO LIST OF FIGURES

FIGURE 01. MYASTHENIA GRAVIS TREATMENT MARKET, 2022-2032

FIGURE 02. SEGMENTATION OF MYASTHENIA GRAVIS TREATMENT MARKET, 2022-2032

FIGURE 03. TOP INVESTMENT POCKETS IN MYASTHENIA GRAVIS TREATMENT MARKET (2023-2032)

FIGURE 04. LOW BARGAINING POWER OF SUPPLIERS

FIGURE 05. LOW BARGAINING POWER OF BUYERS

FIGURE 06. LOW THREAT OF SUBSTITUTES

FIGURE 07. LOW THREAT OF NEW ENTRANTS

FIGURE 08. LOW INTENSITY OF RIVALRY

FIGURE 09. DRIVERS, RESTRAINTS AND OPPORTUNITIES: GLOBALMYASTHENIA GRAVIS TREATMENT MARKET

FIGURE 10. MYASTHENIA GRAVIS TREATMENT MARKET, BY DRUG CLASS, 2022(%)

FIGURE 11. COMPARATIVE SHARE ANALYSIS OF MYASTHENIA GRAVIS TREATMENT MARKET FOR MONOCLONAL ANTIBODIES, BY COUNTRY 2022 AND 2032(%)

FIGURE 12. COMPARATIVE SHARE ANALYSIS OF MYASTHENIA GRAVIS TREATMENT MARKET FOR INTRAVENOUS IMMUNOGLOBULIN, BY COUNTRY 2022 AND 2032(%)

FIGURE 13. COMPARATIVE SHARE ANALYSIS OF MYASTHENIA GRAVIS TREATMENT MARKET FOR OTHERS, BY COUNTRY 2022 AND 2032(%)

FIGURE 14. MYASTHENIA GRAVIS TREATMENT MARKET, BY AGE GROUP, 2022(%)

FIGURE 15. COMPARATIVE SHARE ANALYSIS OF MYASTHENIA GRAVIS TREATMENT MARKET FOR BELOW 55 YEARS, BY COUNTRY 2022 AND 2032(%)

FIGURE 16. COMPARATIVE SHARE ANALYSIS OF MYASTHENIA GRAVIS TREATMENT MARKET FOR ABOVE 55 YEARS, BY COUNTRY 2022 AND 2032(%)

FIGURE 17. MYASTHENIA GRAVIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022(%)

FIGURE 18. COMPARATIVE SHARE ANALYSIS OF MYASTHENIA GRAVIS TREATMENT MARKET FOR HOSPITAL PHARMACIES, BY COUNTRY 2022 AND 2032(%)

FIGURE 19. COMPARATIVE SHARE ANALYSIS OF MYASTHENIA GRAVIS TREATMENT MARKET FOR DRUG STORE AND RETAIL PHARMACIES, BY COUNTRY 2022 AND 2032(%)

FIGURE 20. COMPARATIVE SHARE ANALYSIS OF MYASTHENIA GRAVIS TREATMENT MARKET FOR ONLINE PROVIDERS, BY COUNTRY 2022 AND 2032(%)

FIGURE 21. MYASTHENIA GRAVIS TREATMENT MARKET BY REGION, 2022

FIGURE 22. U.S. MYASTHENIA GRAVIS TREATMENT MARKET, 2022-2032 ($MILLION)

FIGURE 23. CANADA MYASTHENIA GRAVIS TREATMENT MARKET, 2022-2032 ($MILLION)

FIGURE 24. MEXICO MYASTHENIA GRAVIS TREATMENT MARKET, 2022-2032 ($MILLION)

FIGURE 25. GERMANY MYASTHENIA GRAVIS TREATMENT MARKET, 2022-2032 ($MILLION)

FIGURE 26. FRANCE MYASTHENIA GRAVIS TREATMENT MARKET, 2022-2032 ($MILLION)

FIGURE 27. UK MYASTHENIA GRAVIS TREATMENT MARKET, 2022-2032 ($MILLION)

FIGURE 28. ITALY MYASTHENIA GRAVIS TREATMENT MARKET, 2022-2032 ($MILLION)

FIGURE 29. SPAIN MYASTHENIA GRAVIS TREATMENT MARKET, 2022-2032 ($MILLION)

FIGURE 30. REST OF EUROPE MYASTHENIA GRAVIS TREATMENT MARKET, 2022-2032 ($MILLION)

FIGURE 31. JAPAN MYASTHENIA GRAVIS TREATMENT MARKET, 2022-2032 ($MILLION)

FIGURE 32. CHINA MYASTHENIA GRAVIS TREATMENT MARKET, 2022-2032 ($MILLION)

FIGURE 33. INDIA MYASTHENIA GRAVIS TREATMENT MARKET, 2022-2032 ($MILLION)

FIGURE 34. REST OF ASIA-PACIFIC MYASTHENIA GRAVIS TREATMENT MARKET, 2022-2032 ($MILLION)

FIGURE 35. LATIN AMERICA MYASTHENIA GRAVIS TREATMENT MARKET, 2022-2032 ($MILLION)

FIGURE 36. MIDDLE EAST AND AFRICA MYASTHENIA GRAVIS TREATMENT MARKET, 2022-2032 ($MILLION)

FIGURE 37. TOP WINNING STRATEGIES, BY YEAR

FIGURE 38. TOP WINNING STRATEGIES, BY DEVELOPMENT

FIGURE 39. TOP WINNING STRATEGIES, BY COMPANY

FIGURE 40. PRODUCT MAPPING OF TOP 10 PLAYERS

FIGURE 41. COMPETITIVE DASHBOARD

FIGURE 42. COMPETITIVE HEATMAP: MYASTHENIA GRAVIS TREATMENT MARKET

FIGURE 43. TOP PLAYER POSITIONING, 2022

FIGURE 44. ZYDUS LIFESCIENCES LIMITED: NET REVENUE, 2020-2022 ($MILLION)

FIGURE 45. ZYDUS LIFESCIENCES LIMITED: REVENUE SHARE BY SEGMENT, 2022 (%)

FIGURE 46. ZYDUS LIFESCIENCES LIMITED: REVENUE SHARE BY REGION, 2022 (%)

FIGURE 47. NOVARTIS AG: NET SALES, 2020-2022 ($MILLION)

FIGURE 48. NOVARTIS AG: REVENUE SHARE BY SEGMENT, 2022 (%)

FIGURE 49. NOVARTIS AG: REVENUE SHARE BY REGION, 2022 (%)

FIGURE 50. ASTRAZENECA: NET SALES, 2020-2022 ($MILLION)

FIGURE 51. ASTRAZENECA: REVENUE SHARE BY REGION, 2022 (%)

FIGURE 52. BAUSCH HEALTH COMPANIES, INC.: NET REVENUE, 2020-2022 ($MILLION)

FIGURE 53. BAUSCH HEALTH COMPANIES, INC.: REVENUE SHARE BY SEGMENT, 2022 (%)

FIGURE 54. BAUSCH HEALTH COMPANIES, INC.: REVENUE SHARE BY REGION, 2022 (%)

FIGURE 55. CSL LIMITED: SALES REVENUE, 2020-2022 ($MILLION)

FIGURE 56. CSL LIMITED: REVENUE SHARE BY SEGMENT, 2022 (%)

FIGURE 57. CSL LIMITED: REVENUE SHARE BY REGION, 2022 (%)

FIGURE 58. GRIFOLS, S.A.: NET REVENUE, 2020-2022 ($MILLION)

FIGURE 59. GRIFOLS, S.A.: REVENUE SHARE BY SEGMENT, 2022 (%)

FIGURE 60. GRIFOLS, S.A.: REVENUE SHARE BY REGION, 2022 (%)

FIGURE 61. OCTAPHARMA AG: SALES REVENUE, 2020-2022 ($MILLION)

FIGURE 62. ASTELLAS PHARMA INC.: SALES REVENUE, 2020-2022 ($MILLION)

FIGURE 63. ASTELLAS PHARMA INC.: REVENUE SHARE BY REGION, 2022 (%)

FIGURE 64. KEDRION, SPA: NET REVENUE, 2019-2021 ($MILLION)

FIGURE 65. F. HOFFMANN-LA ROCHE LTD.: NET REVENUE, 2020-2022 ($MILLION)

FIGURE 66. F. HOFFMANN-LA ROCHE LTD.: REVENUE SHARE BY SEGMENT, 2022 (%)

FIGURE 67. F. HOFFMANN-LA ROCHE LTD.: REVENUE SHARE BY REGION, 2022 (%